Dr. Stuart Johnson

CutisPharma announces FDA approval for Firvanq

CutisPharma announces FDA approval for Firvanq

WILMINGTON, Mass. — CutisPharma reported that the U.S. Food and Drug Administration has approved Firvanq (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. “We are pleased to announce the FDA approval of Firvanq,” Neal Muni,  chief executive officer of CutisPharma said